Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Phase Two Ventures is a seed venture fund based in San Diego, founded to invest in early-stage life science startups. Established with a mission to support diverse science entrepreneurs, the firm focuses on R&D tools, platform technologies, and computational biology. This focus aims to facilitate advancements in basic research, diagnostics, and therapeutics.
The firm currently manages a portfolio of 10 companies and operates with a check size range of $100K to $500K. Phase Two Ventures has established itself as a key player in the life sciences sector, particularly in the United States. Notable milestones include successful exits such as Mesa Biotech and Sweetspot Diabetes, showcasing the firm's ability to identify and nurture promising startups.
Phase Two Ventures is committed to driving innovation in the biotech field, leveraging its expertise and connections to support entrepreneurs in navigating the complexities of research and development. The firm is strategically positioned in San Diego, a hub for biotech innovation, which enhances its ability to attract and support high-potential startups.
Phase Two Ventures invests primarily in early-stage life science startups, with a particular emphasis on R&D tools, platform technologies, and computational biology. The firm targets sectors such as biotech and healthcare, focusing on innovations that address critical challenges in research and development, diagnostics, and therapeutics. Their investment thesis highlights the potential of technologies that can drive the next generation of scientific discoveries, particularly in areas like multi-omics, bioengineering, synthetic biology, and cell & gene therapies.
The firm typically invests between $100K and $500K in seed-stage companies, allowing them to support a diverse range of startups. Phase Two Ventures seeks founders who demonstrate a strong understanding of their technology and market, as well as a commitment to advancing scientific innovation. The firm values strategic guidance and connections within the biotech ecosystem, which are essential for navigating the complexities of commercialization.
Phase Two Ventures has a diverse portfolio of 10 companies, focusing on innovative solutions in the life sciences sector. Notable portfolio companies include:
This portfolio reflects Phase Two Ventures' commitment to supporting innovative life science technologies that have the potential to transform healthcare.
José Morachis: Founder and Managing Partner. José has extensive experience in venture capital and life sciences, having led numerous investments in early-stage biotech companies.
Will Alaynick: Founder and Managing Partner. Will brings a strong background in life sciences and has been instrumental in building the firm's portfolio.
Mark Nowakowski: Venture Partner. Mark has a deep understanding of the biotech landscape and has previously worked with several successful startups.
Eddie Rodriguez: Venture Partner. Eddie specializes in operational support for portfolio companies, helping them navigate the complexities of commercialization.
Robert Mowry: Venture Partner. Robert has a strong track record in identifying promising life science technologies and supporting their development.
Darlene Solomon: Advisor. Darlene provides strategic insights and guidance based on her extensive experience in the biotech industry.
To pitch Phase Two Ventures, founders should visit their website at phasetwo.vc. It is advisable to include a comprehensive pitch deck that outlines the technology, market potential, and team qualifications. The firm prefers warm introductions but will also consider direct submissions through their website. Response times may vary, but founders can expect to hear back within a few weeks.
Phase Two Ventures has been active in the life sciences sector, recently investing in companies such as Rybodyn, Potato, and Lynx Biosciences. These investments reflect the firm's commitment to supporting innovative solutions in biotech.
Notable exits from the portfolio include Mesa Biotech, acquired by Thermo Fisher, and Sweetspot Diabetes, acquired by Dexcom. These successful exits highlight the firm's ability to identify and nurture high-potential startups in the life sciences space.
What are the investment criteria for Phase Two Ventures?
Phase Two Ventures focuses on early-stage life science startups, particularly those developing R&D tools, platform technologies, and computational biology solutions. The firm seeks companies that address significant challenges in research, diagnostics, and therapeutics.
How can I apply or pitch to Phase Two Ventures?
Founders can submit their pitches through the firm's website at phasetwo.vc. It is recommended to include a detailed overview of the technology, market potential, and team background in the pitch deck.
What makes Phase Two Ventures different from other venture capital firms?
Phase Two Ventures emphasizes support for diverse science entrepreneurs and focuses specifically on life sciences, leveraging its expertise to provide strategic guidance and connections within the biotech ecosystem.
What is the geographic scope of Phase Two Ventures' investments?
The firm primarily invests in startups located in the United States, particularly those based in biotech hubs like San Diego.
What is the typical check size for investments?
Phase Two Ventures typically invests between $100K and $500K in seed-stage companies, allowing them to support a range of early-stage startups.
What kind of post-investment involvement does Phase Two Ventures have?
The firm actively engages with its portfolio companies, providing strategic guidance and facilitating connections to help navigate the complexities of R&D and commercialization.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.